Vericel (VCEL) EBIT Growth (1y) (2011 - 2026)
Powered by 
Analysis
Vericel (VCEL) EBIT Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.26 Bn | 9.41 Bn | 112.79 Mn | 48.27% |
| 2 | CRISPR Therapeutics AG | 5.20 Bn | 5.20 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | 54.38% |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 363.47% |
| 5 | uniQure | 3.06 Bn | 3.06 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.68 Bn | 2.68 Bn | - | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.34 Bn | 1.55 Bn | 251.87 Mn | -88.50% |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 121.39% |
| 10 | Taysha Gene Therapies | 1.99 Bn | 1.99 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 121.39% |
| Mar 31, 2026 | 36.96% |
| Dec 31, 2025 | 21.30% |
| Sep 30, 2025 | 239.96% |
| Jun 30, 2025 | 66.36% |
| Mar 31, 2025 | -134.11% |
| Dec 31, 2024 | 45.15% |
| Sep 30, 2024 | 51.26% |
| Jun 30, 2024 | -1.17% |
| Mar 31, 2024 | 33.18% |
| Dec 31, 2023 | 109.22% |
| Sep 30, 2023 | 25.50% |
| Jun 30, 2023 | 34.36% |
| Mar 31, 2023 | -12.43% |
| Dec 31, 2022 | 46.95% |
| Sep 30, 2022 | -36.83% |
| Jun 30, 2022 | -143.55% |
| Mar 31, 2022 | -120.06% |
| Dec 31, 2021 | -66.30% |
| Sep 30, 2021 | -241.06% |